Our mission is to discover, develop and commercialize innovative and differentiated medicines based on genetically defined targets.

Xenon is a clinical genetics-based drug development company. Independently and through partnerships with leading global pharmaceutical companies, we identify and validate in humans new targets for drug development and convert that knowledge into innovative and differentiated medicines. Our programs focus on indications of important unmet medical need including pain, anemia, iron overload, metabolic and cardiovascular disease. Xenon’s pipeline of products spans discovery through to Phase 2 clinical trials.

News
January 9, 2012 – Xenon to collaborate with Genentech on discovery of novel targeted pain therapeutics.
January 6, 2012 – Xenon publishes new research paper on the treatment of inherited erythromelalgia.